Intake Forms for Genetic Counseling Practices: Why the First Appointment Depends on What You Collect Before It
Genetic counseling is one of the few healthcare specialties where the intake form does not just support the appointment — it defines whether the appointment can happen at all. A cardiologist can take a walk-in, listen to a heart, and start forming a differential. A genetic counselor who sits down with a patient without a completed three-generation pedigree, a clear referral indication, insurance pre-authorization, and documented informed consent for testing has essentially lost the session. They will spend forty-five minutes collecting the information they should have had before the patient walked in, and the patient will leave feeling like they just provided data without receiving guidance.
This is not a complaint about efficiency. It is a clinical reality. Genetic counseling sessions are time-limited — typically thirty to sixty minutes — and the complexity of the information being discussed is enormous. A patient being counseled about BRCA1/2 testing needs to understand penetrance, variant classification, the difference between a pathogenic variant and a variant of uncertain significance, implications for insurance, implications for family members, and the psychological weight of knowing versus not knowing. That conversation cannot happen if the counselor is still drawing a pedigree on scratch paper while the patient sits in silence.
The intake form for a genetic counseling practice, therefore, is not a formality. It is the foundation that makes everything else possible. This guide covers what those forms need to contain, why each section matters clinically and legally, and where most practices get it wrong.
Family history and pedigree construction documentation
The pedigree is the central diagnostic tool in genetics. Every other specialty has imaging, lab values, or physical examination findings as their primary data source. In genetic counseling, the pedigree is that data source. A well-constructed three-generation pedigree can reveal inheritance patterns, identify at-risk relatives, and guide which genetic tests to order — or whether testing is indicated at all.
The intake form needs to collect family history in a structured way that makes pedigree construction efficient. This means going well beyond the typical medical intake question of "any family history of cancer, heart disease, or diabetes?" The genetic counseling intake form should collect, at minimum:
- A complete list of first-degree relatives (parents, siblings, children) with current ages or ages at death, causes of death, and any known diagnoses
- Second-degree relatives (grandparents, aunts, uncles, half-siblings) with the same information
- Third-degree relatives (first cousins) when the referral indication involves a condition with variable expressivity
- Ethnicity and ancestral background for each branch — this is not demographic data collection, it is clinically relevant because certain genetic conditions are significantly more prevalent in specific populations (Tay-Sachs in Ashkenazi Jewish populations, sickle cell trait in individuals of sub-Saharan African descent, cystic fibrosis carrier frequency differences between Northern European and East Asian populations)
- Consanguinity — whether the patient's parents or any relatives in the pedigree are biologically related to each other, which increases the probability of autosomal recessive conditions
- Known genetic test results in any family member — including the specific variant identified, the laboratory that performed the testing, and the date, because variant reclassification happens and a "variant of uncertain significance" from 2015 may have been upgraded or downgraded since then
- Pregnancy losses, stillbirths, and infant deaths across the family, with gestational age and any known cause — this information is often omitted from standard medical histories but is diagnostically critical in genetics
- Adoption status for the patient or any relatives, which creates gaps in the pedigree that must be documented rather than ignored
Many practices use a structured family history questionnaire that patients complete before the appointment, then the counselor converts that raw data into a standardized pedigree using NSGC-recommended symbols during the session. The intake form is not the pedigree itself — it is the raw material from which the pedigree is built. Designing the form so that the information flows naturally into pedigree construction saves significant session time.
One common mistake: asking patients to draw their own family tree. Most patients do not know the conventions, they forget branches, and the result is a hand-drawn diagram that takes longer to interpret than it would have taken to build from structured data. Give them fields to fill in. Let the counselor do the drawing.
Prenatal genetic counseling intake
Prenatal genetic counseling is one of the highest-volume reasons patients are referred to a genetic counselor, and the intake form needs to capture information specific to the pregnancy as well as the broader genetic context.
The obstetric section of the intake form should include:
- Current gestational age and estimated due date (confirmed by ultrasound dating versus last menstrual period)
- Gravidity and parity — the number of pregnancies and their outcomes, including any pregnancies affected by a genetic condition, birth defects, or chromosomal abnormalities
- Maternal age at estimated delivery date — still relevant despite advances in screening because it affects the prior probability calculations used in risk assessment
- Results of any screening tests already performed: first-trimester combined screening (nuchal translucency measurement, PAPP-A, and free beta-hCG), cell-free DNA screening (also called NIPT or noninvasive prenatal testing), quad screen, or sequential screening
- Ultrasound findings — specifically any soft markers or structural anomalies identified, including the date and facility where the ultrasound was performed
- Whether the patient has had carrier screening (expanded carrier panels, targeted screening based on ethnicity, or single-gene carrier tests) and the results
- Partner's carrier screening results, if available, and partner's ethnicity and family history
- Exposure history during the pregnancy — medications, alcohol, recreational drugs, radiation, infections (particularly TORCH infections: toxoplasmosis, rubella, cytomegalovirus, herpes simplex, and now Zika), and occupational exposures
- Assisted reproduction — whether the pregnancy resulted from IVF, ICSI, donor egg, donor sperm, or gestational surrogacy, and whether preimplantation genetic testing (PGT-A, PGT-M, or PGT-SR) was performed
- Maternal medical conditions that affect fetal risk, including pregestational diabetes (which increases the risk of congenital heart defects and neural tube defects), seizure disorders treated with teratogenic medications, and autoimmune conditions
The prenatal intake form also needs to establish what the patient already understands about the reason for the referral. A patient referred because of an abnormal NIPT result for trisomy 21 has a very different starting point than a patient referred for advanced maternal age with all normal screening. The intake form should ask what the patient has been told about the reason for the referral and what questions they are hoping to have answered. This allows the counselor to tailor the session instead of delivering a generic overview.
A note on sensitivity: prenatal intake forms touch on pregnancy loss history, potential fetal diagnoses, and reproductive decision-making. The tone and framing of questions matter. Asking "Have you ever terminated a pregnancy?" in a checkbox format on page two of a medical intake form is clinically insensitive, even though the information is relevant. Better: a narrative field under pregnancy history that asks the patient to describe the outcome of each pregnancy in their own words, with space for context.
Cancer genetics intake
Cancer genetics referrals — for BRCA1/2 testing, Lynch syndrome evaluation, Li-Fraumeni syndrome, hereditary diffuse gastric cancer, and other hereditary cancer syndromes — require an intake form that goes deep on the cancer-specific family history and on the patient's personal cancer history.
The family history section for cancer genetics should capture, for every affected relative:
- Type of cancer (primary site, not just "cancer" — the difference between breast cancer and pancreatic cancer in a family member changes the differential entirely)
- Age at diagnosis for each cancer — hereditary cancer syndromes typically present at younger ages than sporadic cancers, and the age at diagnosis is a critical variable in risk models like Tyrer-Cuzick and BRCAPRO
- Whether the cancer was bilateral (particularly for breast and ovarian cancer)
- Whether the relative had multiple primary cancers
- Whether the relative has had genetic testing and, if so, the result — a family member who tested negative for BRCA1/2 without a known family variant tells you nothing, while a family member who tested positive for a specific pathogenic variant changes the entire workup
- Ashkenazi Jewish ancestry on either side (the three BRCA founder mutations are common enough to affect testing strategy)
- Whether any relative has had a cancer associated with Lynch syndrome — colorectal, endometrial, ovarian, gastric, urinary tract, small bowel, hepatobiliary, or sebaceous gland tumors
For the patient's personal history, the intake form should capture:
- Any personal cancer diagnosis, including pathology details (tumor grade, receptor status for breast cancer, microsatellite instability or immunohistochemistry results for colorectal or endometrial cancer)
- Age at diagnosis
- Treatment received — surgery, chemotherapy, radiation — and current cancer status
- Previous genetic testing — what panel was run, which laboratory, and when, because panel content and variant interpretation change over time
- Whether the patient meets NCCN guidelines for genetic testing based on personal and family history — this affects insurance coverage and can be pre-assessed from the intake form before the session
Cancer genetics intake forms should also ask about the patient's motivation for testing. Some patients are referred by their oncologist and are seeking information to guide treatment decisions (particularly for PARP inhibitor eligibility in BRCA-positive ovarian and breast cancers). Others are unaffected individuals who want to know their risk so they can make decisions about screening and prevention (prophylactic mastectomy, oophorectomy, enhanced surveillance with breast MRI). These are different conversations, and knowing the patient's goals before the session allows the counselor to prepare accordingly.
Pediatric genetics intake
Pediatric genetics referrals cover an enormous clinical range: dysmorphology evaluations for children with multiple congenital anomalies, developmental delay and intellectual disability workups, metabolic disease presentations, skeletal dysplasias, neuromuscular conditions, and evaluation of children with features suggestive of a specific genetic syndrome.
The pediatric genetics intake form needs to capture:
- Pregnancy and birth history — prenatal exposures, prenatal screening and diagnostic results, mode of delivery, birth weight, gestational age, APGAR scores, NICU stay and its duration, and any complications
- Developmental milestones — age at first smile, rolling, sitting independently, crawling, walking, first words, two-word phrases, and current developmental level across domains (gross motor, fine motor, speech-language, social-emotional, cognitive). For older children, academic performance and any educational supports (IEP, 504 plan, special education services)
- Growth parameters — current height, weight, and head circumference, and any history of growth concerns (failure to thrive, macrocephaly, microcephaly, short stature, tall stature)
- Dysmorphic features the parents or referring physician have noted — unusual facial features, hand or foot differences, birthmarks, ear pits or tags, and other physical findings
- Feeding difficulties — particularly in infancy, since many metabolic and genetic conditions present with feeding intolerance, failure to thrive, or specific dietary triggers
- Seizure history — type, frequency, age at onset, and current anticonvulsant medications
- Newborn screening results — whether the newborn screen was normal, and if any follow-up was recommended
- Previous genetic testing — chromosomal microarray, karyotype, fragile X testing, whole exome sequencing, whole genome sequencing, metabolic panels, or single-gene tests, including the laboratory and date
- Behavioral concerns — autism spectrum features, attention difficulties, repetitive behaviors, self-injurious behaviors, and sleep disturbances
- Involvement of other specialists — neurology, cardiology, orthopedics, endocrinology, gastroenterology, ophthalmology, audiology — which tells the counselor about the complexity of the case and the need for coordinated care
The pediatric intake form also needs to handle the relational complexity of genetic conditions in children. The parents filling out the form may be confronting the possibility that their child's condition is inherited, which means one of them may carry the same variant. This creates an emotional dynamic that the counselor needs to be aware of before the session begins. The form can prepare for this by asking whether either parent has any of the features being evaluated in the child, and whether there is concern about recurrence risk for future pregnancies.
Pharmacogenomics and personalized medicine documentation
Pharmacogenomic testing — genetic testing to predict drug metabolism, efficacy, and adverse effects — is increasingly common in genetic counseling practice, and the intake form needs to capture information specific to this indication.
The pharmacogenomics-specific intake fields should include:
- The specific clinical scenario that prompted the referral — adverse drug reaction, treatment failure, pre-prescribing optimization, or a provider wanting to avoid trial-and-error prescribing
- Complete current medication list, including dosages and start dates
- Medication history — drugs that were tried and discontinued, with reasons for discontinuation (lack of efficacy, side effects, adverse reactions)
- Specific adverse drug reactions experienced — what drug, what reaction, timeline, whether it was reported, and outcome
- The therapeutic area of concern — psychiatry (SSRIs, antipsychotics), oncology (fluorouracil, tamoxifen), cardiology (clopidogrel, warfarin), pain management (codeine, tramadol), or others
- Whether the patient is currently under the care of a prescribing provider who will act on the pharmacogenomic results — testing without a clinical action plan is a common frustration in pharmacogenomics
- Previous pharmacogenomic testing results, if any — some patients have had testing through direct-to-consumer services or previous healthcare providers
Pharmacogenomics intake forms should also include an educational consent component. Many patients do not understand that pharmacogenomic testing identifies genetic variants that affect how their body processes drugs — it does not diagnose disease. Conflating pharmacogenomic testing with diagnostic genetic testing leads to misconceptions about what the results mean and what actions follow.
Informed consent for genetic testing: GINA protections and insurance implications
Informed consent for genetic testing is not the same as informed consent for a blood draw. The information generated by genetic testing has implications that extend beyond the patient, beyond the clinical encounter, and potentially across the patient's entire lifetime. The intake form — or the consent document that accompanies it — must address these implications explicitly.
The core informed consent elements for genetic testing include:
- The purpose of the specific test being considered and what conditions it evaluates
- What the test can and cannot detect — including limitations of the technology (e.g., exome sequencing may miss structural variants, repeat expansions, or deep intronic variants)
- Possible results: positive (pathogenic variant identified), negative (no pathogenic variant identified), and inconclusive (variant of uncertain significance, or VUS) — with an explanation that a VUS is not actionable and may be reclassified in the future
- Implications for family members — a positive genetic test result in one person has direct implications for biological relatives, and the patient should understand that the counselor may recommend sharing results with family members, though the patient is never obligated to do so
- The right to decline testing — genetic testing is always voluntary, even when the referring physician recommended it
- Sample storage and re-analysis policies of the testing laboratory — whether the laboratory retains DNA, whether the patient will be re-contacted if a VUS is reclassified, and whether the sample may be used for research
GINA — the Genetic Information Nondiscrimination Act — deserves its own section on the consent form, because patients consistently overestimate or underestimate its protections. GINA prohibits health insurance companies and employers from discriminating based on genetic information. It does not, however, cover life insurance, disability insurance, or long-term care insurance. For a 28-year-old considering BRCA testing who does not yet have a long-term disability policy, this is an important distinction. For a 55-year-old with established insurance policies, the calculus is different.
The intake form should include a clear, plain-language summary of what GINA does and does not protect, and a field for the patient to acknowledge that they have been informed of these limitations. This is not just good practice — it is a risk management safeguard for the practice. A patient who later discovers that a positive genetic test result affected their ability to obtain life insurance may claim they were never told. The signed consent form, with its GINA disclosure, is the documentation that the conversation happened.
Insurance pre-authorization information should also be collected at intake. Many genetic tests require prior authorization from the patient's insurance company, and the intake form should capture:
- Insurance carrier, plan type, and member ID
- Whether the patient has a deductible that has not been met
- Whether the patient is willing to proceed with testing if insurance denies coverage — some genetic tests cost several hundred to several thousand dollars out of pocket, depending on the panel and the laboratory
- Whether the patient wants the practice to pursue a peer-to-peer review if the initial authorization is denied
Some practices use the intake form to pre-screen for insurance coverage by asking about NCCN guideline criteria directly. For cancer genetics, if the patient does not meet criteria, the form can document the rationale for why testing is being considered anyway (cascade testing in a family with a known variant, for example), which strengthens the authorization request.
Psychosocial assessment and readiness for genetic test results
Not every patient who walks into a genetic counseling appointment is ready to receive a result. This is a dimension of genetic counseling that distinguishes it from almost every other healthcare specialty, and the intake form needs to capture it.
The psychosocial section of the intake form should assess:
- The patient's current understanding of the condition they are being evaluated for — what have they been told by the referring provider, what have they read or looked up, and what do they believe the test will show?
- Prior experiences with genetic conditions in the family — watching a parent die of Huntington disease at age 45 shapes the emotional experience of genetic testing in ways that cannot be captured by a clinical history alone
- Current mental health status — active depression, anxiety, or other psychiatric conditions that may affect the patient's ability to process results
- Support system — does the patient have a partner, family members, or friends they have discussed testing with? Will they be bringing someone to the appointment?
- Anticipated response to a positive result — has the patient thought about what they would do if the test confirmed a hereditary condition? This is not a hypothetical question; for presymptomatic testing, the answer to this question determines whether the counselor proceeds with testing or recommends additional counseling sessions first
- Religious, cultural, or personal beliefs that may affect decision-making about testing, reproductive choices, or medical management after a positive result
- Whether the patient is being pressured by family members to undergo testing — genetic testing should be an autonomous decision, and coercion by relatives (particularly in the context of family planning) is a contraindication for proceeding without additional sessions to ensure the decision is the patient's own
The psychosocial assessment on the intake form is not a substitute for the counselor's in-session assessment. It is a preview. It allows the counselor to identify patients who may need more time, more sessions, or a referral to a psychologist or psychiatrist before testing proceeds. For presymptomatic testing for conditions like Huntington disease, the established protocol includes multiple counseling sessions before testing, precisely because the psychological impact of a positive result is so profound that the counselor has an ethical obligation to ensure the patient is prepared.
Reproductive planning and preconception counseling
A significant portion of genetic counseling referrals involve reproductive planning — either preconception counseling for couples planning a pregnancy, or postconception counseling for couples who have already conceived and are navigating screening or diagnostic results.
The reproductive planning intake form should capture:
- The couple's reproductive goals — are they actively trying to conceive, considering pregnancy in the future, or dealing with recurrent pregnancy loss?
- Known carrier status for either partner — from expanded carrier screening, targeted screening, or a known family history
- Previous pregnancies affected by a genetic condition, birth defect, or chromosomal abnormality — including the specific diagnosis, the outcome of the pregnancy, and any testing that was performed on the pregnancy or the affected child
- Recurrence risk questions — many couples seek preconception counseling specifically to understand the probability that a future pregnancy would be affected by the same condition that affected a previous child or pregnancy
- Interest in reproductive options — preimplantation genetic testing with IVF (PGT-M), prenatal diagnosis via CVS or amniocentesis, use of donor gametes, or adoption. This question helps the counselor prepare materials and referrals for the session
- Religious or ethical considerations that may limit which reproductive options the couple is willing to consider — some couples will pursue PGT-M but not prenatal diagnosis with the option of termination; others will pursue natural conception with prenatal monitoring but no invasive testing
- Whether the couple has consulted with a reproductive endocrinologist or fertility specialist — the coordination between genetic counseling and fertility treatment is important, particularly when PGT-M is being considered
Reproductive intake forms need to be written with care. The language should be neutral about reproductive choices. A form that asks "Would you terminate an affected pregnancy?" is not the same as a form that asks "What reproductive options would you like to discuss?" The latter invites an open conversation; the former imposes a binary framework on a deeply personal decision.
Ethical considerations in predictive testing
Predictive genetic testing — testing an asymptomatic individual for a genetic condition they may develop later in life — raises ethical questions that do not arise in most other areas of medicine. The intake form for predictive testing needs to document that these ethical dimensions have been considered.
Huntington disease is the paradigmatic case. HD is caused by a CAG repeat expansion in the HTT gene, and it is fully penetrant: a person with 40 or more repeats will develop the disease, typically between ages 30 and 50. There is no cure and no disease-modifying treatment. Predictive testing for HD has been available since 1993, and the international guidelines developed by the International Huntington Association and the World Federation of Neurology include specific requirements:
- A minimum of two counseling sessions before testing, with a "cooling off" period between the decision to test and the blood draw
- A neurological examination to confirm the patient is presymptomatic (if the patient already shows symptoms, the testing is diagnostic, not predictive, and the protocol is different)
- Psychological assessment, including screening for depression, suicidal ideation, and the availability of a support person
- Informed consent that specifically addresses the inability to "un-know" a positive result
- A plan for results disclosure, including who will be present and what follow-up is arranged
The intake form for predictive testing should document that the patient has been informed of the testing protocol, that they have had the opportunity to ask questions, and that they have a support system in place. It should also document any family dynamics that may complicate the process — for example, if the patient's at-risk parent does not know their own status and would effectively have their status revealed by the patient's test result.
Similar ethical considerations apply to presymptomatic testing for hereditary cancer syndromes in young adults, for familial amyloid polyneuropathy, for certain cardiomyopathies, and for early-onset Alzheimer disease associated with PSEN1, PSEN2, or APP variants. In each case, the intake form must capture enough psychosocial context for the counselor to determine whether testing is appropriate at this time or whether additional preparation is needed.
Predictive testing of minors adds another layer. The general consensus in the genetics community, codified in position statements from the ACMG, ASHG, and NSGC, is that predictive testing of minors should be deferred until adulthood unless there is a medical intervention available in childhood that would change management. The intake form should ask the age of the patient being considered for testing and, if the patient is a minor, the medical rationale for testing now rather than waiting.
Direct-to-consumer genetic test interpretation referrals
An increasing proportion of genetic counseling referrals now come from patients who have taken a direct-to-consumer (DTC) genetic test — 23andMe, AncestryDNA, or one of the many health-focused DTC panels — and are seeking interpretation of their results. This is a distinct clinical scenario that requires its own intake documentation.
The DTC interpretation intake form should capture:
- Which DTC company performed the testing and when
- What type of testing was performed — genotyping array (which is what most DTC tests use, as opposed to sequencing) and which health reports were generated
- What specific result or results the patient is concerned about — a BRCA variant flagged by 23andMe's health report, an APOE4 allele associated with Alzheimer disease risk, carrier status for a recessive condition, or pharmacogenomic results
- Whether the patient has already shared these results with their primary care provider or another specialist
- The patient's understanding of the limitations of DTC testing — specifically, that DTC genotyping tests only a small number of variants in each gene and is not equivalent to clinical-grade sequencing. A "negative" DTC result for BRCA does not mean the patient does not carry a BRCA pathogenic variant — it means the patient does not carry one of the specific variants included on the DTC panel
- Whether the patient has uploaded their raw data to third-party interpretation services (Promethease, Genetic Genie, or others) and what those interpretations said — third-party raw data interpretation is unregulated and frequently produces false positives that require clinical follow-up
DTC referrals present a unique counseling challenge because the patient has already received a result — possibly a frightening one — without the context that a genetic counselor would normally provide before testing. The intake form for these patients should also include a psychosocial check: how long has the patient known about this result, how are they coping with it, and what action have they taken or avoided since receiving it? A patient who received a DTC BRCA result six months ago and has been too anxious to follow up is in a different psychological state than a patient who received the result last week and immediately called for an appointment.
Coordination with ordering physicians and specialists
Genetic counselors rarely work in isolation. Most genetic testing is ordered by or in coordination with a referring physician — an oncologist, obstetrician, pediatrician, neurologist, or primary care provider. The intake form needs to capture the information necessary for this coordination.
- Referring physician's name, practice, phone, fax, and preferred method of communication for results
- Whether the referring physician has specific clinical questions they want the genetic counseling session to address — this is different from the patient's questions, and both need to be documented
- Other specialists involved in the patient's care who should receive a copy of the counseling summary and test results
- The patient's primary care provider, if different from the referring physician
- Whether the referring provider has already ordered genetic testing and wants the counselor to provide pre-test counseling only, or whether the counselor is expected to order the testing
- Consent for the counselor to communicate results and recommendations to the referring provider and other specialists — this is distinct from HIPAA authorization and should be explicitly documented
In many clinical settings, the genetic counselor's note is the primary means by which the referring physician receives the risk assessment, test results, and management recommendations. The intake form that captures the referral details ensures the counselor knows exactly who needs to receive information and in what format.
Incidental findings disclosure preferences
Broad genetic testing — whole exome sequencing, whole genome sequencing, and large multi-gene panels — has created a clinical and ethical challenge that did not exist when genetic testing meant a single-gene test for a single indication. These broad tests can identify pathogenic variants that are unrelated to the reason for testing. A child undergoing exome sequencing for developmental delay may be found to carry a pathogenic BRCA1 variant. An adult undergoing cardiac genetic testing may be found to carry a variant associated with Lynch syndrome.
The ACMG has published a recommended list of genes for which incidental (or secondary) findings should be reported to patients, currently containing 81 genes associated with conditions where knowledge of the variant would lead to actionable medical intervention. But the decision of whether to receive these findings is ultimately the patient's.
The intake form should document the patient's preferences regarding incidental findings:
- Does the patient want to receive medically actionable incidental findings?
- Does the patient want to receive carrier status information (relevant for reproductive planning but not for the patient's personal health)?
- Does the patient want to receive pharmacogenomic findings?
- Does the patient understand that some findings may have implications for insurance (see GINA limitations above)?
- If the patient is a minor, do the parents want to receive adult-onset incidental findings, or defer those until the child reaches adulthood?
This section of the intake form should not be a simple yes/no checkbox. The patient needs to understand what incidental findings are, what kinds of information they might include, and what the implications of knowing versus not knowing might be. Many practices use a tiered consent model, where the patient can opt in to some categories of incidental findings and opt out of others. The intake form should accommodate this tiered approach rather than forcing an all-or-nothing decision.
Documenting incidental findings preferences at intake — before the test is ordered — is essential. Retroactively asking a patient whether they want to hear about an incidental finding after the result is already in the chart creates an impossible clinical situation. The preferences must be established and documented before the blood is drawn.
Insurance, billing, and financial counseling
Genetic testing costs range from under $100 for a targeted single-variant test to over $10,000 for whole genome sequencing with comprehensive interpretation. Insurance coverage is inconsistent, varies by plan, and changes frequently. The intake form is where you capture the information needed to navigate this landscape before the patient is sitting in the chair expecting a test to be ordered.
Beyond basic insurance information, the genetic counseling intake form should capture:
- Whether the patient has any religious or ethical objections to genetic testing that might affect which laboratory is selected (some laboratories have affiliations or policies that matter to certain patients)
- Whether the patient has previously been denied insurance coverage for genetic testing and the reason given
- The patient's preferred laboratory, if any — some patients have loyalty to a specific lab because of previous positive experiences with patient support or financial assistance programs
- Whether the patient is aware of laboratory financial assistance programs — many genetic testing laboratories (Invitae, GeneDx, Ambry, Myriad) offer reduced-cost or no-cost testing for patients who meet certain financial criteria
- Out-of-pocket maximum the patient is willing to pay if insurance coverage is not obtained
Capturing this information at intake allows the genetic counselor or the practice's financial coordinator to begin the pre-authorization process before the appointment, which means the patient can potentially have testing ordered at the first visit rather than requiring a follow-up visit after insurance approval is obtained.
Documentation for laboratory selection and test ordering
Unlike most medical tests, genetic testing is not standardized across laboratories. The same "BRCA panel" at two different laboratories may sequence different regions of the gene, include different numbers of genes, use different bioinformatics pipelines, and apply different variant classification frameworks. The intake form needs to capture the clinical details that inform laboratory and test selection.
The counselor needs to know:
- What previous genetic testing the patient has had, at which laboratory, and when — to avoid redundant testing and to identify whether updated testing with current technology would be informative
- Whether a family member has had testing and, if so, whether a familial variant has been identified — cascade testing (testing for a known family variant) is simpler, cheaper, and more definitive than testing the entire gene
- The patient's insurance network — some laboratories are in-network for some insurance plans and out-of-network for others, which dramatically affects cost
- Whether the patient's ethnicity or ancestry suggests a testing strategy that starts with targeted variant analysis rather than full gene sequencing (for example, the three Ashkenazi Jewish BRCA founder mutations can be tested as a first step before proceeding to full BRCA1/2 sequencing)
This information feeds directly into the pre-session preparation that makes genetic counseling appointments efficient. A counselor who knows before the session which laboratory to use, which test to order, and whether insurance is likely to cover it can use the session time for counseling rather than logistics.
Structuring the intake form for clinical flow
The order in which sections appear on the form matters more in genetic counseling than in most specialties, because the information builds on itself. A logical structure for a genetic counseling intake form follows this sequence:
- Patient demographics and contact information — including legal name, preferred name, pronouns, date of birth, and contact details
- Referral information — referring provider, reason for referral, and specific clinical questions
- Insurance and billing — captured early so the financial counseling process can begin immediately
- Personal medical history — with emphasis on conditions relevant to the referral indication
- Family history — the pedigree questionnaire, which is typically the longest section
- Indication-specific history — the prenatal, cancer, pediatric, pharmacogenomic, or reproductive section relevant to this patient's referral
- Previous genetic testing — in the patient and in family members
- Psychosocial assessment — readiness, support, coping
- Incidental findings preferences — if broad testing is being considered
- Informed consent for genetic testing — including GINA disclosure
- Authorization for communication with providers — the list of providers who should receive the counseling summary and results
This structure allows the counselor to review the form before the session and identify the most pressing issues. A form that jumps between demographics, family history, consent, more family history, and insurance makes it difficult to get a quick clinical picture. A well-ordered form tells the counselor a coherent story before the patient even sits down.
Common pitfalls in genetic counseling intake forms
Having reviewed intake forms from dozens of genetic counseling practices, the same problems recur:
- Using a general medical intake form without genetic counseling-specific sections. A form designed for a primary care practice does not ask about pedigree information, variant reclassification, incidental findings, or GINA. It captures demographics and allergies, and leaves the counselor with nothing to work with.
- Asking for family history in narrative format only. "Please describe your family history of genetic conditions" produces wildly variable responses that are difficult to convert into a pedigree. Structured fields for each relative produce more complete and more usable data.
- Omitting the psychosocial assessment. Every genetics professional organization recommends psychosocial assessment as part of genetic counseling, yet many intake forms skip it entirely. This leaves the counselor discovering mid-session that the patient is not ready for testing — a discovery that wastes the session and may harm the patient.
- GINA language that is too complex. The typical GINA disclosure on a consent form reads like it was written by a regulatory attorney for an audience of other regulatory attorneys. If the patient cannot understand it, it is not informed consent. Use plain language. Provide examples. Explain what GINA covers (health insurance and employment) and what it does not (life insurance, disability insurance, long-term care insurance) in terms the patient can understand.
- No mechanism for updating the intake form. Genetic counseling often involves multiple visits over time, and family history changes. Relatives are diagnosed with new conditions. VUS results are reclassified. Children reach developmental milestones or fail to reach them. The intake form should have a mechanism for updates — either a "family history update" addendum form or a section for the counselor to document changes at follow-up visits.
- Treating all referral indications the same. A prenatal patient and a cancer genetics patient need different information collected. Using one monolithic intake form for all indications either forces the patient to complete irrelevant sections or forces the counselor to skip sections that are relevant. Modular forms with a shared demographics/insurance section and indication-specific supplements are more effective.
The intake form as clinical tool
A genetic counseling intake form, done well, is not paperwork the patient fills out in the waiting room and the counselor glances at before the session. It is a clinical instrument that shapes the encounter. The pedigree data guides the risk assessment. The psychosocial assessment determines the pace and depth of the counseling. The incidental findings preferences set the scope of testing. The insurance information determines whether testing can be ordered at this visit or requires pre-authorization.
When the intake form is well-designed and thoroughly completed, the counselor can spend the session doing what only a counselor can do: explaining complex genetic concepts in accessible language, helping the patient weigh the risks and benefits of testing, facilitating informed and autonomous decision-making, and providing emotional support during a process that is often frightening and always consequential.
When the intake form is poorly designed or incomplete, the counselor spends the session being a data entry clerk. The patient leaves with fewer answers than they came in with, and the practice bills for a counseling session that was mostly intake. Neither the patient nor the practice benefits.
The investment in a comprehensive, well-structured, specialty-specific intake form pays for itself immediately. Every minute saved by pre-session data collection is a minute the counselor can spend on the work that matters: helping patients and families understand their genetic information and make informed decisions about their health.
Professional intake forms for healthcare practices
Fillable PDF intake forms and client questionnaires designed for healthcare professionals. Ready to download, fill, and use today.
Also available: the Healthcare Bundle — 21 complete intake form sets for healthcare and wellness practices at a bundled discount.
Not ready to buy? Download our free Universal Intake Form — a fillable PDF you can use today, no purchase needed.